## Amendment to the claims:

## 1-33. (canceled)

- 34. (new) A method for TGF-β screening comprising:
- measuring ex vivo a TGF-β level in a body sample of a human or a veterinary animal, wherein the body sample is blood or a fraction thereof;
- incubating the body sample with a compound selected from the group of a flavanol, a procyanidin and a mixture thereof, and measuring the resulting TGF-β level;
- (iii) comparing the TGF-β level obtained in step (i) with the TGF β level obtained in step (ii);
- (iv) when the TGF-β level obtained in step (i) is higher than the TGF-β level obtained in step (ii), designating the human or the veterinary animal as a high baseline TGF-β producer; or when the TGF-β level obtained in step (i) is lower than the TGF-β level obtained in step (ii), designating the human or the veterinary animal as a low baseline TGF-β producer.
- 35. (new) The method of claim 34, wherein the compound in step (ii) is epicatechin.
- 36. (new) The method of claim 34, wherein the compound in step (ii) is a procyanidin dimer.
  - 37. (new) The method of claim 34, wherein TGF-β is TGF-β1.
- 38. (new) The method of claim 34, further comprising the step of selecting a composition comprising a TGF-β modulating amount of a flavanol, a procyanidin and/or a mixture thereof.
  - 39. (new) The method of claim 38, wherein TGF-\(\beta\) is TGF-\(\beta\)1.
- 40. (new) The method of claim 38, wherein the human or the veterinary animal is a low baseline TGF- $\beta$  producer, the flavanol is epicatechin, and the procyanidin is selected from the group of a dimer, trimer, tetramer and pentamer.

{W:\DOCS\NJPC\1010\0133us1\00007722,DOC1

2

US Appl. Ser. No. 10/725,805 Filed December 2, 2003 Amendment and Response filed: February 09, 2007

- 41. The method of claim 40, wherein TGF-β is TGF-β1.
- 42. (new) The method of claim 38, wherein the human or the veterinary animal is a low baseline TGF- $\beta$  producer, and the composition comprises a TGF- $\beta$  modulating amount of epicatechin.
- 43. (new) The method of claim 34, further comprising the step of selecting a composition comprising an effective amount of a compound having TGF-β modulating properties.
  - 44. (new) The method of claim 42, wherein TGF-β is TGF-β1.
- 45. (new) The method of claim 37, wherein the human or the veterinary animal is a high baseline TGF-β producer, and the procyanidin is at least one procyanidin oligomer 6-10.
  - 46. (new) The method of claim 45, wherein TGF-β is TGF-β1.
  - 47. (new) The method of claim 38, further comprising the step of administering the composition to the human or the veterinary animal.
  - 48. (new) The method of claim 38, wherein the composition is a food.
  - 49. (new) The method of claim 38, wherein the food is a beverage.
  - 50. (new) The method of claim 38, wherein the composition is chocolate.
  - 51. (new) The method of claim 38, wherein the composition is a dietary supplement.
  - 52. (new) The method of claim 38, wherein the composition is a cocoa extract.
  - 53. (new) The method of claim 38, wherein the composition is a cocoa ingredient.